Chemed
CHE on NYSE. Chemed sells hospice care and plumbing services to patients and homeowners. Market value $6.7bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Worth a closer look
Why it could be worth it
What to watch out for
Nothing stood out in the numbers we check.
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $4.86 of spare cash in the past 12 months. A savings account pays about $4.
You pay 19.4 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Quality score: 75 of 100. Price score: 69 of 100. Our list needs 70 on quality and 60 on price.
$509.84 a share, 40% above its 1-year low
Over the past year the price has ranged from $365.21 to $557.00.
Dividend: 0.5% a year
Paid every year for at least 5 years
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $2.1bn | $2.1bn | $2.3bn | $2.4bn | $2.5bn |
| Operating margin | |||||
| Operating margin | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| Debt to equity | |||||
| Debt to equity | 0.30 | 0.12 | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.01bn | 0.02bn | 0.01bn | 0.01bn | 0.01bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)5 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsSlow, 4.0% a year
- Buying back its own sharesYes, 12% fewer since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $673 million last quarter, up 9% on a year ago.
- Profit: $68 million, up 29% on a year ago.
- It keeps 13 cents of each $1 of sales as operating profit, down from 15 cents a year earlier.
- Spare cash over the past 12 months: $324 million, down from $371 million.
- 10% fewer shares than a year ago. Each share owns a bit more of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $606m |
| December 2024 | $640m |
| March 2025 | $647m |
| June 2025 | $619m |
| September 2025 | $625m |
| December 2025 | $639m |
| March 2026 | $658m |
| June 2026 | $673m |
| Quarter to | Amount |
|---|---|
| September 2024 | $76m |
| December 2024 | $90m |
| March 2025 | $72m |
| June 2025 | $52m |
| September 2025 | $64m |
| December 2025 | $77m |
| March 2026 | $66m |
| June 2026 | $68m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 27 February 2026
- Next quarterly (estimated, 10-Q)
- 30 October 2026
Who owns it
4 long-term investors we follow own it, up from 3 last quarter. 530 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Boston PartnersBoston Partners team | $131m | 0.1% | New |
| Gotham Asset ManagementJoel Greenblatt | $43m | 0.1% | Added |
| Fenimore Asset Management (FAM Funds)John Fox | $17m | 0.4% | Added |
| GAMCO InvestorsMario Gabelli | $10m | <0.1% | Cut |
Largest holders overall
- BlackRock$691mAdded
- AQR Capital Management$446mAdded
- Vanguard Portfolio Management$367mCut
- Vanguard Capital Management$282mCut
- Acadian Asset Management$211mAdded
- State Street$207mCut
- Geode Capital Management$193m
- JPMorgan Chase$186mCut
- Boston Partners$131mNew
- Epoch Investment Partners$124mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- AQR Capital Management, LLCPassive investorat least 7.2%(filed with 1 related holder)Since 30 June 2026
- Vanguard Portfolio ManagementPassive investor5.9%Since 31 March 2026
- Vanguard Capital ManagementPassive investor5.4%Since 31 March 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
AQR Capital Management, LLC Passive investor | at least 7.2% (filed with 1 related holder) | 30 June 2026 | |
Vanguard Portfolio Management Passive investor | 5.9% | 31 March 2026 | |
Vanguard Capital Management Passive investor | 5.4% | 31 March 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 5 sold $9m.
- MCNAMARA KEVIN Jpresident and CEO, DirectorSold
- Date
- 28 September 2026
- Shares
- 2,000
- Price
- $513.45
- Value
- $1m
- MCNAMARA KEVIN Jpresident and CEO, DirectorSold
- Date
- 18 September 2026
- Shares
- 2,000
- Price
- $501.40
- Value
- $1m
- LEE SPENCER Sexecutive vice presidentSold
- Date
- 21 August 2026
- Shares
- 1,000
- Price
- $541.04
- Value
- $541,040
- MCNAMARA KEVIN Jpresident and CEO, DirectorSold
- Date
- 21 August 2026
- Shares
- 2,000
- Price
- $541.16
- Value
- $1m
- MCNAMARA KEVIN Jpresident and CEO, DirectorSold
- Date
- 3 August 2026
- Shares
- 2,000
- Price
- $539.51
- Value
- $1m
- GRACE PATRICK PDirectorSold
- Date
- 31 July 2026
- Shares
- 190
- Price
- $532.00
- Value
- $101,080
- LINDELL ANDREA RDirectorSold
- Date
- 9 June 2026
- Shares
- 1,347
- Price
- $447.33
- Value
- $602,554
- WALSH GEORGE J IIIDirectorSold
- Date
- 29 May 2026
- Shares
- 500
- Price
- $437.83
- Value
- $218,915
- GRACE PATRICK PDirectorSold
- Date
- 8 May 2026
- Shares
- 60
- Price
- $425.78
- Value
- $25,547
- MCNAMARA KEVIN Jpresident and CEO, DirectorSold
- Date
- 1 May 2026
- Shares
- 2,000
- Price
- $421.13
- Value
- $842,260
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 28 September 2026 | MCNAMARA KEVIN J president and CEO, Director | Sold | 2,000 | $513.45 | $1m |
| 18 September 2026 | MCNAMARA KEVIN J president and CEO, Director | Sold | 2,000 | $501.40 | $1m |
| 21 August 2026 | LEE SPENCER S executive vice president | Sold | 1,000 | $541.04 | $541,040 |
| 21 August 2026 | MCNAMARA KEVIN J president and CEO, Director | Sold | 2,000 | $541.16 | $1m |
| 3 August 2026 | MCNAMARA KEVIN J president and CEO, Director | Sold | 2,000 | $539.51 | $1m |
| 31 July 2026 | GRACE PATRICK P Director | Sold | 190 | $532.00 | $101,080 |
| 9 June 2026 | LINDELL ANDREA R Director | Sold | 1,347 | $447.33 | $602,554 |
| 29 May 2026 | WALSH GEORGE J III Director | Sold | 500 | $437.83 | $218,915 |
| 8 May 2026 | GRACE PATRICK P Director | Sold | 60 | $425.78 | $25,547 |
| 1 May 2026 | MCNAMARA KEVIN J president and CEO, Director | Sold | 2,000 | $421.13 | $842,260 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 27 Feb 2026, plus the 10-Q filed 31 Jul 2026 and 4 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
What changed in the risks this year
Companies must list what could hurt them each year. These are the parts that changed since last year’s report.
Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.
Could happenBoth Roto-Rooter’s and VITAS’s primary businesses are the provision of services within the United States. Accordingly, they are likely to be less affected by the impact of specific or wide-ranging tariffs than many other entities in the United States and Global economies. However, significant tariffs on certain products, such as steel for Roto-Rooter’s cabling machines and pharmaceuticals utilized by VITAS, could materially increase the costs of Roto-Rooter and VITAS. Additionally, because our service businesses heavily rely on delivering service to customers or patients in their residences, increases in the costs of vehicle acquisition, maintenance, repair, and reimbursement for employees’ use of personal vehicles, could have a significant increase on our expenses.
Read moreSignificant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.
Could happenIf, as a result of tariffs, the United States’ economy experiences a recession or other economic slowdown, the demand for Roto-Rooter’s non-emergency services may decline materially.
Liability claims may have an adverse effect on VITAS, and its insurance coverage may be inadequate.
Already happenedDespite significant safeguards, including active intrusion protection, firewalls and virus detection software, as discussed in greater detail on Item 1C below, in October of 2025, access to our systems was gained by a threat actor in a cybersecurity attack. The threat actor was able to access a significant amount of Protected Health Information (“PHI”); however, despite repeated attempts, was not able to insert a tool often used by threat actors into our system. Our response plan was effective in identifying, quarantining, and eliminating the third-party intrusion, but not before access to PHI was gained.
Read moreSignificant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.
Could happenTo the extent that tariffs cause any adverse impacts on global supply chains, it could further materially affect the ability of both businesses to timely source critical supplies, which may affect our delivery of services.
Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.
Could happenThese additional costs, in the case of VITAS, cannot be passed along to our patients because of the structure of hospice reimbursement, and in the case of Roto-Rooter, may not be able to be fully passed along to our customers. These additional costs could materially adversely affect our margins.
Read more
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.